The median time‐to‐treatment failure (TTF) for initial tyrosine kinase inhibitor (TKI) therapy was 308 days for the high CYFRA21‐1:CEA ratio group and 617 days for the low CYFRA21‐1:CEA ratio group for ALK‐positive lung cancer (p = 0.100). This evidence concerns the gene ALK and lung carcinoma.